MHRA issues alert for missing information on Atrolak XL tablet leaflets
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
List view / Grid view
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
A report suggests that instead of taxing medical device imports, the Indian government should offer tax rebates to multinational companies if they partner with domestic device manufacturers.
The government in the UK has told pharmaceutical businesses to examine the risk that coronavirus poses to the supply chain and retain any stockpiles from Brexit to mitigate shortages.
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
In a formal ceremony, the new headquarters for Novartis has been opened in White City, London, in close proximity to Imperial College London’s research campus.
The developers have announced solanezumab failed to show disease-modifying properties against dominantly inherited Alzheimer's disease (DIAD).
The two agencies have signed a statement of their intent to combat anti-competitive practices which are preventing the adoption of biosimilars in the US drug market.
EFPIA, Medicines for Europe and AESGP have called for a Mutual Recognition Agreement on good manufacturing practice in regards to the future relationship between the UK and the EU.
According to its developers, SAR442168 significantly reduced the appearance of new gadolinium (Gd)-enhancing T1-hyperintense brain lesions in the 120 trial patients.
Research has found that technological innovation and legislation are to drive the growth of the global anti-counterfeit packaging market.
A report has outlined the opportunities and challenges for the pharmaceutical industry in south-east Asia, including implementing a track and trace system as well as generics potential.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
A team of industry experts awarded Nemera’s Safe’n’Spray with a prestigious Pharmapack Award for ‘Best Innovation in Drug Delivery Device’.
The FDA has granted Investigational New Drug (IND) authorisation to KP1237 for the treatment of multiple myeloma using a patient's own Natural Killer cells.
A study showed that bone stem cells rearrange degrading microporous annealed particle (MAP) hydrogels, promoting their growth.